Putting the award page together from the records…
Putting the award page together from the records…
IGF::OT::IGF
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
6 actions since 2022-12-14. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-09-25 | P00018 | Option exercised | $277.82M | INMAZEB EBOLA THERAPEUTICS |
| 2026-07-30 | P00017 | Change order | $2.68M | INMAZEB EBOLA THERAPEUTICS |
| 2025-08-06 | P00016 | Change order | $0 | NO COST MOD TO REVISE THE CONTRACT SECTIONS: ARTICLE B.4 AND F.4 |
| 2024-12-06 | P00015 | Change order | $0 | NO COST MOD TO REVISE THE CONTRACT SECTIONS: ARTICLE B.2.1., ARTICLE C.1., ARTICLE F.4, , ARTICLE G.4. AND THE STATEMENT OF WORK. |
| 2023-11-07 | P00014 | Administrative change | $0 | NO COST MOD TO REVISE THE CONTRACT SECTIONS: ARTICLE B.2.2., B.4.Q., ARTICLE C.1., ARTICLE F.4, AND THE STATEMENT OF WORK. ADD ARTICLE B.4.R., ARTICLE H.31., AND FAR CLAUSE 52.204-27. |
| 2022-12-14 | P00013 | Change order | $0 | EBOLA THERAPEUTICS |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-21). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗